An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity

Cell Death and Disease

Volumn 3, Issue 8, 2012, Pages

  Cisbani, G ^a   Cicchetti, F ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aggregates; In vitro models; Inducible pluripotent stem cells; Inflammation; Mutant huntingtin

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE;

APOPTOSIS; ASTROCYTE; CAG REPEAT; CELL LINE; CELL MIGRATION; CELL ORGANELLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOSOL; CYTOTOXICITY; EMBRYO DEVELOPMENT; ENDOCYTOSIS; EXCITOTOXICITY; EXOCYTOSIS; EXON; GAIN OF FUNCTION MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MICROGLIA; MICROTUBULE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OLIGODENDROGLIA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW;

CELL SURVIVAL; HUMANS; HUNTINGTON DISEASE; MUTATION; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN INTERACTION MAPS;

EID: 84865770337     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.121     Document Type: Review

References (158)

1. Rothlind JC, Bylsma FW, Peyser C, Folstein SE, Brandt J. Cognitive and motor correlates of everyday functioning in early Huntington's disease. J Nerv Ment Dis 1993; 181: 194-199. (Pubitemid 23090176)
2. Ross CA, Shoulson I. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord 2009; 15(Suppl 3): S135-S138.
3. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577. (Pubitemid 16196286)
4. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-930. (Pubitemid 41753086)
5. Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009; 19: 147-155.
6. Smith R, Brundin P, Li JY. Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol Life Sci 2005; 62: 1901-1912. (Pubitemid 41261838)
7. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000; 97: 6763-6768. (Pubitemid 30412788)
8. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001; 24: 182-188. (Pubitemid 32166824)
9. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006; 96: 1121-1129.
10. Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 2003; 87: 101-106. (Pubitemid 37210644)
11. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60: 1202-1210. (Pubitemid 27194105)
12. Djousse L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A 2003; 119A: 279-282. (Pubitemid 37063854)
13. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506. (Pubitemid 26374323)
14. Di Figlia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993. (Pubitemid 27449140)
15. Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol 1997; 7: 979-1002. (Pubitemid 27346738)
16. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90: 549-558. (Pubitemid 27347244)
17. Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 1998; 24: 217-233. (Pubitemid 29316230)
18. Xue WF, Hellewell AL, Gosal WS, Homans SW, Hewitt EW, Radford SE. Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 2009; 284: 34272-34282.
19. Dahlgren KN, Manelli AM, Stine WB Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053. (Pubitemid 34969015)
20. Cenini G, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G et al. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 2010; 38: 1101-1106.
21. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet 2003; 19: 233-238. (Pubitemid 36511427)
22. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 2009; 219: 385-397.
23. Giorgini F, Muchowski PJ. Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol 2005; 6: 210.
24. Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998; 18: 1261-1269. (Pubitemid 28082412)
25. Metzler M, Legendre-Guillemin V, Gan L, Chopra V, Kwok A, McPherson PS et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem 2001; 276: 39271-39276.
26. Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, Worm U et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004; 15: 853-865. (Pubitemid 39277983)
27. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001; 276: 24713-24718.
28. Housman D. Gain of glutamines, gain of function? Nat Genet 1995; 10: 3-4.
29. Squitieri F, Almqvist EW, Cannella M, Cislaghi G, Hayden MR. Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clin Genet 2003; 64: 524-525. (Pubitemid 37493126)
30. Trushina E, Dyer RB, Badger JD II, Ure D, Eide L, Tran DD et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004; 24: 8195-8209. (Pubitemid 39167467)
31. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81: 294-330. (Pubitemid 46528643)
32. Dragatsis I, Dietrich P, Zeitlin S. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse. Neurosci Lett 2000; 282: 37-40. (Pubitemid 30129163)
33. Zheng S, Clabough EB, Sarkar S, Futter M, Rubinsztein DC, Zeitlin SO. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet 2010; 6: e1000838.
34. Clabough EB, Zeitlin SO. Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro. Hum Mol Genet 2006; 15: 607-623. (Pubitemid 43205425)
35. Sipione S, Cattaneo E. Modeling Huntington's disease in cells, flies, and mice. Mol Neurobiol 2001; 23: 21-51. (Pubitemid 32948271)
36. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498. (Pubitemid 32679077)
37. Cannella M, Maglione V, Martino T, Ragona G, Frati L, Li GM et al. DNA instability in replicating Huntington's disease lymphoblasts. BMC Med Genet 2009; 10: 11.
38. Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001; 98: 12784-12789. (Pubitemid 33020022)
39. Johri A, Beal MF. Hunting-ton for new proteases: MMPs as the new target? Neuron 2010; 67: 171-173.
40. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18: 150-154. (Pubitemid 28082462)
41. Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Regulier E et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem 2008; 104: 846-858.
42. Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA et al. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Philos Trans R Soc Lond Ser B 1999; 354: 1047-1055. (Pubitemid 29477966)
43. Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease Hum Mol Genet 1999; 8: 25-33. (Pubitemid 29039045)
44. Huang B, Schiefer J, Sass C, Kosinski CM, Kochanek S. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion. J Gene Med 2008; 10: 269-279. (Pubitemid 351359639)
45. Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 2005; 20: 785-798. (Pubitemid 41622214)
46. Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 2001; 10: 1829-1845. (Pubitemid 32899099)
47. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003; 361: 1642-1644. (Pubitemid 36579005)
48. Hands SL, Wyttenbach A. Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathol 2010; 120: 419-437.
49. Kaytor MD, Wilkinson KD, Warren ST. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity. J Neurochem 2004; 89: 962-973. (Pubitemid 38684743)
50. Poirier MA, Jiang H, Ross CA. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 2005; 14: 765-774. (Pubitemid 40403273)
51. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 2002; 277: 41032-41037. (Pubitemid 35215693)
52. Ossato G, Digman MA, Aiken C, Lukacsovich T, Marsh JL, Gratton E. A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys J 2010; 98: 3078-3085.
53. Rajan RS, Illing ME, Bence NF, Kopito RR. Specificity in intracellular protein aggregation and inclusion body formation. Proc Natl Acad Sci USA 2001; 98: 13060-13065. (Pubitemid 33051317)
54. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810. (Pubitemid 39434070)
55. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 2002; 35: 9-12. (Pubitemid 34804316)
56. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003; 12: 749-757. (Pubitemid 36416961)
57. Webb JL, Ravikumar B, Rubinsztein DC. Microtubule disruption inhibits autophagosome- lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. Int J Biochem Cell Biol 2004; 36: 2541-2550. (Pubitemid 39119765)
58. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997; 42: 604-612. (Pubitemid 27439023)
59. Wang GH, Mitsui K, Kotliarova S, Yamashita A, Nagao Y, Tokuhiro S et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuro Report 1999; 10: 2435-2438. (Pubitemid 29418115)
60. Pennuto M, Palazzolo I, Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet 2009; 18: R40-47.
61. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009; 64: 828-840.
62. Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet 2011; 20: 1424-1437.
63. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28: 425-433. (Pubitemid 36976745)
64. Davranche A, Aviolat H, Zeder-Lutz G, Busso D, Altschuh D, Trottier Y et al. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Hum Mol Genet 2011; 20: 2795-2806.
65. Chen S, Berthelier V, Yang W, Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 2001; 311: 173-182. (Pubitemid 32735322)
66. Wang Y, Meriin AB, Costello CE, Sherman MY. Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders. Prion 2007; 1: 128-135.
67. Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 2006; 8: 1163-1170. (Pubitemid 44473613)
68. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004; 23: 4307-4318. (Pubitemid 39546168)
69. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004; 15: 95-105. (Pubitemid 38850222)
70. Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. Polyglutamine protein aggregates are dynamic. Nat Cell Biol 2002; 4: 826-831.
71. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 1998; 4: 755-757. (Pubitemid 28331004)
72. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282-11286. (Pubitemid 23354413)
73. Yoshimoto M, Iwai A, Kang D, Otero DA, Xia Y, Saitoh T. NACP the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci USA 1995; 92: 9141-9145.
74. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci Lett 2000; 289: 29-32. (Pubitemid 30433838)
75. Corrochano S, Renna M, Carter S, Chrobot N, Kent R, Stewart M et al. Alpha-Synuclein levels modulate Huntington's disease in mice. Hum Mol Genet 2012; 21: 485-494.
76. Tomas-Zapico C, Diez-Zaera M, Ferrer I, Gomez-Ramos P, Moran MA, Miras-Portugal MT et al. Alpha-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. Hum Mol Genet 2012; 21: 495-510.
77. Furlong RA, Narain Y, Rankin J, Wyttenbach A, Rubinsztein DC. Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. Biochem J 2000; 346(Part 3): 577-581. (Pubitemid 30171015)
78. Herrera F, Outeiro TF. Alpha-Synuclein modifies huntingtin aggregation in living cells. FEBS Lett 2012; 586: 7-12.
79. Caparros-Lefebvre D, Kerdraon O, Devos D, Dhaenens CM, Blum D, Maurage CA et al. Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity? Mov Disord 2009; 24: 1089-1090.
80. Schwab C, Yu S, McGeer EG, McGeer PL. Optineurin in Huntington's disease intranuclear inclusions. Neurosci Lett 2012; 506: 149-154.
81. Hortobagyi T, Troakes C, Nishimura AL, Vance C, van Swieten JC, Seelaar H et al. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol 2011; 121: 519-527.
82. Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull 2008; 75: 146-157. (Pubitemid 350297653)
83. Henshall TL, Tucker B, Lumsden AL, Nornes S, Lardelli MT, Richards RI. Selective neuronal requirement for huntingtin in the developing zebrafish. Hum Mol Genet 2009; 18: 4830-4842.
84. Soulet D, Cicchetti F. The role of immunity in Huntington's disease. Mol Psychiatry 2011; 16: 889-902.
85. Turner C, Cooper JM, Schapira AH. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord 2007; 22: 1715-1721. (Pubitemid 47597594)
86. Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-3065.
87. Orth M, Cooper JM, Bates GP, Schapira AH. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J Neurochem 2003; 87: 1-6. (Pubitemid 37210633)
88. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81: 811-823.
89. Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem 2001; 76: 442-449. (Pubitemid 32097022)
90. Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm 2010; 117: 77-83.
91. Manley K, Pugh J, Messer A. Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. Brain Res 1999; 835: 74-79. (Pubitemid 29336552)
92. Maywood ES, Fraenkel E, McAllister CJ, Wood N, Reddy AB, Hastings MH et al. Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding. J Neurosci 2010; 30: 10199-10204.
93. Chiang MC, Chern Y, Juo CG. The dysfunction of hepatic transcriptional factors in mice with Huntington's disease. Biochim Biophys Acta 2011; 1812: 1111-1120.
94. Smith R, Bacos K, Fedele V, Soulet D, Walz HA, Obermuller S et al. Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet 2009; 18: 3942-3954.
95. Cape A, Chen X, Wang CE, O'Neill A, Lin YF, He J et al. Loss of huntingtin-associated protein 1 impairs insulin secretion from pancreatic beta-cells. Cell Mol Life Sci 2012; 69: 1305-1317.
96. Metzler M, Helgason CD, Dragatsis I, Zhang T, Gan L, Pineault N et al. Huntingtin is required for normal hematopoiesis. Hum Mol Genet 2000; 9: 387-394. (Pubitemid 30098732)
97. Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 2006; 127: 217-220. (Pubitemid 43165622)
98. Maglione V, Cannella M, Gradini R, Cislaghi G, Squitieri F. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mech Ageing Dev 2006; 127: 213-216. (Pubitemid 43165621)
99. Squitieri F, Maglione V, Orobello S, Fornai F. Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. J Neural Transm 2011; 118: 1599-1607.
100. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003; 2: 366-374. (Pubitemid 38352564)
101. Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, Mariotti C et al. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 2003; 17: 2148-2150.
102. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171: 1001-1012.
103. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106: 22480-22485.
104. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285: 10653-10661.
105. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008; 28: 3277-3290. (Pubitemid 351469331)
106. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010; 19: 3053-3067.
107. Chen LL, Wu JC, Wang LH, Wang J, Qin ZH, Difiglia M et al. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes. Acta Pharmacol Sin 2012; 33: 385-392.
108. Wang L, Lin F, Wang J, Wu J, Han R, Zhu L et al. Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF. Brain Res 2012; 1449: 69-82.
109. Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A et al. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage 2007; 36: 28-37. (Pubitemid 46617949)
110. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130(Part 7): 1759-1766. (Pubitemid 47343790)
111. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72: 148-151. (Pubitemid 46389550)
112. Silvestroni A, Faull RL, Strand AD, Moller T. Distinct neuroinflammatory profile in postmortem human Huntington's disease. Neuro Report 2009; 20: 1098-1103.
113. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J Exp Med 2008; 205: 1869-1877.
114. Giorgini F, Moller T, Kwan W, Zwilling D, Wacker JL, Hong S et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 2008; 283: 7390-7400.
115. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-548. (Pubitemid 27347243)
116. Kraft AD, Kaltenbach LS, Lo DC, Harry GJ. Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol Aging 2012; 33: 621 e617-633.
117. Ma L, Morton AJ, Nicholson LF. Microglia density decreases with age in a mouse model of Huntington's disease. Glia 2003; 43: 274-280. (Pubitemid 37047683)
118. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007; 55: 1074-1084. (Pubitemid 47066747)
119. Tydlacka S, Wang CE, Wang X, Li S, Li XJ. Differential activities of the ubiquitin- proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008; 28: 13285-13295.
120. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011; 472: 319-324.
121. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-1191. (Pubitemid 43866195)
122. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 2006; 80: 165-176. (Pubitemid 44821504)
123. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69. (Pubitemid 44466642)
124. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J Neurosci 2011; 31: 9544-9553.
125. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006; 8: 2061-2073. (Pubitemid 46489631)
126. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397-408. (Pubitemid 44572377)
127. Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46: 41-51.
128. Castiglioni V, Onorati M, Rochon C, Cattaneo E. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol Dis 2012; 46: 30-40.
129. Ritch JJ, Valencia A, Alexander J, Sapp E, Gatune L, Sangrey GR et al. Multiple phenotypes in Huntington disease mouse neural stem cells. Mol Cell Neurosci 2012; 50: 70-81.
130. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
131. Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 2001; 38: 450-452. (Pubitemid 32661206)
132. Song C, Perides G, Liu YF. Expression of full-length polyglutamine- expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 2002; 277: 6703-6707. (Pubitemid 34968473)
133. Colby DW, Cassady JP, Lin GC, Ingram VM, Wittrup KD. Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol 2006; 2: 319-323. (Pubitemid 43787213)
134. Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet 2008; 17: 345-356.
135. Ye C, Zhang Y, Wang W, Wang J, Li H. Inhibition of neurite outgrowth and promotion of cell death by cytoplasmic soluble mutant huntingtin stably transfected in mouse neuroblastoma cells. Neurosci Lett 2008; 442: 63-68. (Pubitemid 352033666)
136. Olshina MA, Angley LM, Ramdzan YM, Tang J, Bailey MF, Hill AF et al. Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 2010; 285: 21807-21816.
137. Wang HQ, Xu YX, Zhao XY, Zhao H, Yan J, Sun XB et al. Overexpression of F(0)F(1)-ATP synthase alpha suppresses mutant huntingtin aggregation and toxicity in vitro. Biochem Biophys Res Commun 2009; 390:1294-1298.
138. Dong G, Ferguson JM, Duling AJ, Nicholas RG, Zhang D, Rezvani K et al. Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells. Cell Mol Neurobiol 2011; 31: 737-747.
139. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci 2010; 30:10541-10550.
140. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998; 7:1355-1361. (Pubitemid 28429913)
141. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 2002; 11:1953-1965. (Pubitemid 34919271)
142. Igarashi S, Morita H, Bennett KM, Tanaka Y, Engelender S, Peters MF et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 2003; 14: 565-568. (Pubitemid 36528991)
143. Aiken CT, Tobin AJ, Schweitzer ES. A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 2004; 16: 546-555. (Pubitemid 38942987)
144. Weiss A, Roscic A, Paganetti P. Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction. Mol Neurodegener 2009; 4:11.
145. Podolsky S, Leopold NA. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 1977; 23: 55-63.
146. Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009; 4: e8025.
147. Garewal HS, Leibovitz A, Sampliner RE, Ramsey L, Hendrix MJ, Sloan D. Tissue culture of epithelial cells from esophageal specialized columnar epithelium (Barrett's esophagus). Dig Dis Sci 1992; 37: 532-536.
148. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20: 3092-3114. (Pubitemid 40007304)
149. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA et al. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 2006; 13: 2068-2078. (Pubitemid 44742690)
150. Boesgaard TW, Nielsen TT, Josefsen K, Hansen T, Jorgensen T, Pedersen O et al. Huntington's disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol 2009; 21: 770-776.
151. Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersen A et al. Testicular degeneration in Huntington disease. Neurobiol Dis 2007a; 26: 512-520. (Pubitemid 46756321)
152. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 2007b; 26: 189-200. (Pubitemid 46436497)
153. Almeida S, Sarmento-Ribeiro AB, Januario C, Rego AC, Oliveira CR. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochem Biophys Res Commun 2008; 374: 599-603.
154. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008; 117: 2743-2751. (Pubitemid 351770455)
155. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813-822. (Pubitemid 29189048)
156. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 25: 297-308. (Pubitemid 46127844)
157. Yoshida Y, Yamanaka S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation 2010; 122: 80-87.
158. Sreejit P, Kumar S, Verma RS. An improved protocol for primary culture of cardiomyocyte from neonatal mice. In Vitro Cell Dev BiolAnim 2008; 44: 45-50.